{
    "abstract": "A fixed-dose combination of HP/TAZ has demonstrated efficacy with a favorable safety profile for treating moderate-to-severe plaque psoriasis.\nThe present single-arm, open-label study evaluated the use of HP/TAZ in real-world practice.\nAdults with moderate-to-severe psoriasis were enrolled and treated with HP/TAZ according to the Canadian label. The primary endpoint was the percentage of patients with treatment success at week 8, defined as an Investigator's Global Assessment score of clear or almost clear with a minimum 2-grade improvement.\n202 patients received at least one dose of HP/TAZ, 138 patients had efficacy assessments at baseline and week 8. Treatment success was achieved by 26.1% and 43.5% of patients (week 4 and 8 respectively) . Patient-rated average and worst itch were 4.5 and 5.3 points at baseline, with a subsequent reduction to 1.7 and 2.1 points, respectively, at week 8. Patients were satisfied-very satisfied with the HP/TAZ. Application site reactions (13.4%) and dermatitis/eczema (3.5%) were the most frequently reported adverse events (mild-moderate in severity) .\nThe study design may limit generalizability of the results as an open label real world evidence study lacking a placebo or comparator arm.\nResults confirm that HP/TAZ can be beneficial moderate-to-severe psoriasis patients.",
    "authors": [
        {
            "affiliation": "Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Dermatrials Research Inc, Hamilton, Ontario, Canada.",
            "firstname": "R",
            "initials": "R",
            "lastname": "Vender"
        },
        {
            "affiliation": "Probity Medical Research Inc, Waterloo, Ontario, Canada; Lynderm Research Inc., Markham, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada.",
            "firstname": "C",
            "initials": "C",
            "lastname": "Lynde"
        },
        {
            "affiliation": "Division of Dermatology, Department of Medicine, University of Calgary, Section of Community Pediatrics, Department of Pediatrics, Section of Pediatric Rheumatology, Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, Calgary, Alberta, Canada.",
            "firstname": "V",
            "initials": "V",
            "lastname": "Prajapati"
        },
        {
            "affiliation": "Bausch Health Companies, Laval, Quebec, Canada. Electronic address: rami.abouzeinab@bauschhealth.com.",
            "firstname": "R",
            "initials": "R",
            "lastname": "Zeinab"
        },
        {
            "affiliation": "Bausch Health Companies, Laval, Quebec, Canada.",
            "firstname": "M",
            "initials": "M",
            "lastname": "Legault"
        },
        {
            "affiliation": "University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, British Columbia, Canada.",
            "firstname": "Hc-H",
            "initials": "HH",
            "lastname": "Hong"
        },
        {
            "affiliation": "Bausch Health Companies, Laval, Quebec, Canada.",
            "firstname": "M",
            "initials": "M",
            "lastname": "Barakat"
        }
    ],
    "conclusions": "Results confirm that HP/TAZ can be beneficial moderate-to-severe psoriasis patients.",
    "copyrights": "Copyright \u00a9 2025 Elsevier Inc. All rights reserved.",
    "doi": "10.1016/j.clinthera.2025.03.005",
    "journal": "Clinical therapeutics",
    "keywords": [
        "Combination",
        "Corticosteroid",
        "Psoriasis",
        "Retinoid",
        "Topical"
    ],
    "methods": null,
    "publication_date": "2025-04-20",
    "pubmed_id": "40253236",
    "results": "202 patients received at least one dose of HP/TAZ, 138 patients had efficacy assessments at baseline and week 8. Treatment success was achieved by 26.1% and 43.5% of patients (week 4 and 8 respectively) . Patient-rated average and worst itch were 4.5 and 5.3 points at baseline, with a subsequent reduction to 1.7 and 2.1 points, respectively, at week 8. Patients were satisfied-very satisfied with the HP/TAZ. Application site reactions (13.4%) and dermatitis/eczema (3.5%) were the most frequently reported adverse events (mild-moderate in severity) .",
    "title": "A Canadian Real-World Study of Fixed-DOSE combination of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for the Treatment of Moderate-to-Severe Plaque Psoriasis.",
    "xml": "<Element 'PubmedArticle' at 0x7885024c3650>"
}